[Featured Stock] Shinpung Pharmaceutical Rises on Confirmation of Piramex's 99% Inhibition of COVID-19 Virus
[Asia Economy Reporter Minwoo Lee] Shares of Shinpung Pharmaceutical are on the rise following news that its antimalarial drug product has reconfirmed its inhibitory effect against the novel coronavirus infection (COVID-19).
As of 10:50 AM on the 3rd, Shinpung Pharmaceutical's stock price is trading at 15,150 KRW, up 27.85% from the previous day.
This appears to be due to reports that Shinpung Pharmaceutical's antimalarial drug 'Piramex' is being considered for drug repurposing as a COVID-19 treatment. Drug repurposing is the process of developing an already approved existing drug into a new treatment.
Hot Picks Today
"Only Two Per Person" Garbage Bag Crisis Was Just Yesterday... Japan Also Faces Shortage Anxiety
- "Samsung Electronics Employee with 100 Million Won Salary Receiving 600 Million Won Bonus... Estimated Tax Revealed"
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- 'Will Demand Finally Decline Due to High Prices?'... "I'll Just Enjoy Nearby Trips" as Japan and China See a Surge
- "Wore It Once, Then This? White Spots All Over 4.15 Million Won Prada Jacket... 'Full Refund Ordered'"
Shinpung Pharmaceutical confirmed through in vitro tests on infected cells that the main components of Piramex, pyronaridine phosphate and artesunate, each have inhibitory effects on the COVID-19 virus. When the two components were combined, they observed a viral titer inhibition rate of over 99% after 24 hours, with sustained effects up to 48 hours, while cytotoxicity decreased. This result is superior to the control drugs chloroquine and lopinavir (a component of Kaletra). Chloroquine is a component recommended as a candidate drug for COVID-19 treatment.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
